Skip to main content
. 2025 Aug 26;20:456. doi: 10.1186/s13023-025-03987-8

Table 1.

Demographics

Variable Parents Unaffected siblings Partners
Participant (n/N) 81/100 13/100 6/100
Sex (male%) 36% (29/81) 54% (7/13) 50% (6/6)
Continent (%)
Europe 52% (42/81) 69% (9/13) 50% (3/6)
North-America 28% (23/81) 23% (3/13) 17% (1/6)
South-America 15% (10/81) 8% (1/13) 17% (1/6)
Other 7% (6/81) 0% (0/13) 17% (1/6)
Age of the unaffected family member
Mean (± SD) 45.3 (11.0) 25.4 (12.7) 52.4 (11.2)
Median (IQR) 43.6 (38.0–50.3) 23.6 (14.9–29.1) 55.6 (44.6–61.5)
Multiple affected individuals (yes%) 17% (14/81) 31% (4/13) NA
Multiple unaffected individuals (yes%) 73% (59/81) 69% (9/13) NA
VWM patients (n/N) 67/74 15/74 6/74
Age
Mean (± SD) 14.0 (± 9.9) 25.2 (± 16.6) 51.9 (± 13.2)
Median (IQR) 12.0 (6.7– 17.3) 20.0 (13.5–32.6) 54.3 (43.0–60.8)
Adult patients (%) 22% (15/67) 53% (8/15) 100% (6/6)
Sex (male%) 57% (38/67) 47% (7/15) 50% (3/6)
Disease duration
Mean (± SD) 9.7 (± 8.8) 15.7 (± 10.0) 11.3 (± 7.9)
Median (IQR) 7.4 (2.7–14.1) 14.0 (10.9–18.2) 12.0 (4.5–15.3)
Age of disease onset
Mean (± SD) 4.3 (± 3.5) 9.5 (± 9.4) 40.6 (± 18.8)
Median (IQR) 3.0 (2.0–5.0) 5.5 (4.0–13.5) 46.5 (25.0- 49.3)
Episodes of rapid decline (yes%) 70% (47/67) 80% (12/15) 100% (6/6)
Loss of walking without support (yes%) 69% (46/67) 73% (11/15) 50% (3/6)
Loss of walking with support (yes%) 48% (32/67) 40% (6/15) 33% (2/6)
Tube feeding (yes%) 13% (9/67) 0% (0/15) 0% (0/6)
Cognitive decline (yes%) 42% (28/67) 67% (10/15) 83% (5/6)
Seizures (yes%) 34% (23/67) 20% (3/15) 33% (2/6)
Behavioral problems (yes%) 46% (31/67) 44% (7/15) 50% (3/6)

N, number; N, total number; NA, Not Applicable; SD, standard deviation; IQR, interquartile range